Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Pharm Res. 2022 Feb 15;39(7):1523–1534. doi: 10.1007/s11095-022-03186-1

Table 1.

Liposome characterization

Sample Size (nm) PDI Drug-Loading (%) Encapsulation Efficiency (%)
Lipo 86.0 ± 0.6 0.133 ± 0.007 - -
2-PAM@Lipo 89.5 ± 0.6a 0.062 ±0.023b 4.7 ± 0.4% 33.9 ± 3.2%
2-PAM@46.1-Lipo 88.2 ± 0.1 0.084 ± 0.011 4.4 ± 0.4% 30.6 ± 3.3%
2-PAM@Ctrl-Lipo 88.1 ± 1.9 0.096 ± 0.042 4.6 ± 0.2% 31.7 ± 2.1%
2-PAM@46.1-Lipo (30 days) 93.6 ± 3.2 nmc 0.194 ± 0.069 - -
2-PAM@Ctrl-Lipo (30 days) 91.6 ± 0.3 nmd 0.073 ± 0.017 - -
a

Size for Lipo versus 2-PAM@Lipo, p<0.05

b

PDI for Lipo versus 2-PAM@Lipo, p<0.05

c

Size for 2-PAM@46.1-Lipo (30days) versus 2-PAM@46.1-Lipo, no change, p>0.05

d

Size for 2-PAM@Ctrl-Lipo (30days) versus 2-PAM@Ctrl-Lipo, no change, p>0.05

All other comparisons: p > 0.05, no significant differences among groups from 2-PAM@Lipo, 2-PAM@46.1-Lipo and 2-PAM@Ctrl-Lipo for hydrodynamic size, PDI, DL and EE by one-way ANOVA followed by Tukey’s HSD test.